{"entity":{"id":"pyxis-oncology","kind":"company","name":"Pyxis Oncology","aka":["Pyxis Oncology, Inc.","Pyxis Oncology, Inc"],"tldr":"A listed Boston company developing an antibody-drug conjugate, a drug that carries a toxin into the tumour, aimed at a protein found in the tissue around cancers. It is in early trials, mainly for head and neck cancer that has come back or spread.","summary":"Pyxis Oncology develops antibody-drug conjugates and immunotherapy antibodies. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an ADC with an auristatin payload that targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tumour's extracellular matrix rather than a protein on the cancer cell. It is in Phase 1 as a single agent (NCT05720117) and with pembrolizumab (NCT06795412, Phase 1/2, with Merck Sharp & Dohme as collaborator), with a focus on recurrent or metastatic head and neck squamous cell carcinoma. The company says the FDA granted Fast Track designation for R/M HNSCC that has progressed after platinum chemotherapy and an anti-PD-(L)1 therapy. Pyxis trades on Nasdaq under PYXS according to its SEC filings.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://pyxisoncology.com/"},{"label":"Clinical programs and pipeline","url":"https://pyxisoncology.com/clinical-programs/"},{"label":"ClinicalTrials.gov NCT05720117","url":"https://clinicaltrials.gov/study/NCT05720117"},{"label":"ClinicalTrials.gov NCT06795412","url":"https://clinicaltrials.gov/study/NCT06795412"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001782223"},{"label":"RA Capital portfolio entry","url":"https://www.racap.com/portfolio/pyxis-oncology"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-hnscc"],"sections":["adcs"],"technologies":["adc"],"targets":["fn1"],"drugs":["micvotabart-pelidotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06795412"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read.","The FN1 target link is for EDB+FN, a splice variant of fibronectin 1.","NCT05720117 was confirmed through the ClinicalTrials.gov v2 API but is not yet a trial record in OnCo."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://pyxisoncology.com/","ticker":"NASDAQ: PYXS","stage":"public","investors":["ra-capital"],"funding":[]},"route":"/companies/pyxis-oncology/","neighbours":{"cancer":[{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/"}],"drug":[{"id":"micvotabart-pelidotin","kind":"drug","name":"Micvotabart pelidotin","route":"/drugs/micvotabart-pelidotin/"}],"trial":[{"id":"nct05720117","kind":"trial","name":"A Study of PYX-201 in Advanced Solid Tumors","route":"/trials/nct05720117/"},{"id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/"}],"company":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}